WHERE WE ARE TODAY WITH MIGS

The Trabecular Meshwork and Schlemm Canal

iStent Trabecular Micro-Bypass Stent

BY LEON W. HERNDON, MD

The number of people suffering from glaucoma worldwide is expected to exceed 70 million by 2020, making the need for safe, effective treatment greater than ever. The popularity of microinvasive glaucoma surgery has been growing, because these procedures can effectively and consistently reduce IOP with distinctly low complication rates and shorter recovery times, in many cases eliminating the need for medication. The iStent Trabecular Micro-Bypass Stent (Glaukos; Figure) has proven to be effective. Draining aqueous flow into Schlemm canal from the anterior chamber, effectively bypassing the damaged or blocked trabecular meshwork, the device can help lower IOP and manage mild to moderate glaucoma without the significant cost, inconvenience, and adherence issues often associated with the use of topical medical therapy. There are other ab interno procedures that target the trabecular meshwork (discussed elsewhere in this issue), but the iStent is the only device currently available that is left in Schlemm canal, allowing for continuous aqueous outflow. (See Watch It Now.)

SAFETY AND EFFICACY

Although cataract surgery on its own modestly reduces IOP, numerous clinical trials have now shown that the implantation of a single iStent in conjunction with the cataract procedure can result in an even greater reduction of IOP and decrease the patient’s need for medications. The pivotal trial illustrated the device’s excellent safety and efficacy profile. With regard to efficacy, 66% of iStent subjects achieved an IOP reduction of at least 20% without medication at 1 year compared to only 48% of the control group. The impeccable safety record of cataract surgery was maintained with the iStent.

MORE STENTS

As surgeons’ overall understanding of the iStent’s effectiveness increases, new possibilities arise. Currently in the United States, the device is indicated for use in conjunction with cataract surgery to reduce IOP in patients with mild to moderate glaucoma who are being treated with medication. If one stent does not produce the desired outcome, the iStent is titratable, although implanting multiple devices is an off-label use in this country. The placement of two or three stents in a solo procedure has also been found to be effective in lowering IOP and reducing or eliminating the need for medication.
THE NEXT GENERATION

The iStent Inject (Glaukos) is not yet approved by the FDA and is currently being studied for use both in conjunction with cataract surgery and as a solo procedure. The iStent Inject comes loaded with two stents, which can be inserted a few clock hours apart in the same procedure. In trials, this device has maintained the safety and efficacy profile of the first-generation iStent.10-12


RESULTS

Enrollment is complete in the Hydrus IV Pivotal Trial, a prospective, multicenter, single-masked, controlled, randomized trial in patients with mild to moderate glaucoma undergoing cataract surgery. The trial has 556 subjects with a 2:1 randomization, making it the largest MIGS study conducted so far. Patients will undergo follow-up evaluation at the 1- and 2-year time points. Expected to close in a few years, the study will be fundamental to analysis of the device’s efficacy during the US regulatory review process.

The Hydrus II study was similar to the Hydrus IV in method (see Watch It Now on p. 26). Results of the 100 patients (1:1 randomization) showed that the percentage with a 20% reduction in washed-out diurnal IOP was higher in patients undergoing Hydrus implantation combined with cataract surgery versus the MIGS procedure alone (80% vs 46%, P = .0008; Figure 2) at 24 months. The proportion of patients who were free of medication was also higher in the combined group (73% vs 38%, P = .0008).2 Adverse events were similar in both groups except for the formation of peripheral access to Schlemm canal. The Hydrus is designed to be implanted in conjunction with cataract surgery. The implantation technique is relatively quick through the same small incisions created during cataract surgery (see Watch It Now on p. 26).

Hydrus Microstent

BY OLUWATOSIN U. SMITH, MD

The Hydrus Microstent (Ivantis) is an intracanalicular scaffold for the treatment of primary open-angle glaucoma. The 8-mm stent is made from a highly flexible, biocompatible alloy of nickel and titanium (Nitinol), which has been used in different medical devices. The 1-mm inlet segment rests in the anterior chamber, while the 7-mm scaffold segment resides in the lumen of Schlemm canal without obstructing collector channel ostia located along the posterior wall (Figure 1). This microinvasive glaucoma surgery (MIGS) device has been shown to increase outflow facility and reduce outflow resistance in perfusion models of human cadaver eyes.1

TECHNIQUE

The Hydrus is currently in FDA phase 3 trials. The stent is only available as an investigational device in the United States, but it is available for use in other countries. The device falls into the trabecular bypass category of MIGS—bypassing trabecular resistance as aqueous gains direct

Figure 1. The Hydrus Microstent in situ. Reprinted with permission of Elsevier from Pfeiffer et al.3
anterior synechiae, which was the only noted adverse event related to the device.

A recent prospective interventional case series compared the Hydrus to selective laser trabeculoplasty (SLT) for the treatment of primary open-angle glaucoma. The MIGS group achieved a significant reduction in IOP and medication use, whereas the SLT group obtained a decrease in IOP only. Postoperatively, 47% of Hydrus patients were medication free versus 4% of the SLT group.

CONCLUSION

The Hydrus appears to be unique in its ability to scaffold Schlemm canal over several clock hours while creating a connection with the anterior chamber unlike other trabecular bypass devices/procedures. In addition, the Hydrus has the advantage of potentially avoiding scarring in the angle, because trabecular meshwork is not removed and is minimally traumatized at the point of the device’s insertion. Based on the published studies, the sustained IOP reduction at the 24-month time point will make this MIGS device a useful option for IOP reduction in patients when the procedure is performed in combination with cataract surgery. Although the data are promising so far, US surgeons must await the results of the Hydrus IV study.


Ab Interno Canaloplasty Using the iTrack 250A Microcatheter

BY MAHMOUD A. KHAIMI, MD

Microinvasive glaucoma surgery (MIGS) has emerged as a safe alternative to conventional surgeries for patients with mild to moderate open-angle glaucoma (OAG). The notable downside of MIGS procedures is that they treat specific areas of the outflow tract, even though there is no way of knowing that the pathology lies only in the treated area. This limitation was the impetus for the development of ab interno canaloplasty (ABiC). Unlike other MIGS procedures, ABiC treats the whole drainage system, thereby removing the “guesswork.”

DIFFERENCES

With stent-based MIGS, the aim is to bypass the diseased trabecular meshwork by placing the distal end of the device in Schlemm canal and the anterior end in the anterior chamber. No diagnostic tool exists, however, for visualizing the exact site of obstruction in OAG. For that reason, surgeons simply cannot determine how much of the canal or outflow system is not working. There is therefore a chance that the area of blockage will be missed or suboptimally treated.

ABiC, in contrast, opens up the whole outflow system and viscodilates all sites involved in the control of aqueous outflow. This stent-free procedure is performed with an illuminated microcatheter (iTrack 250A; Ellex) that is inserted via a corneal microincision (1.8 mm). It restores the natural outflow pathway with minimal tissue trauma and leaves no foreign body (tensioning suture or stent) in the eye.

ABiC is also the only MIGS procedure that addresses collector channel blockages, which studies have shown can be caused by herniated trabecular meshwork tissue. ABiC’s viscodilation opens these herniations to restore full access to collector channel ostia for aqueous outflow.

RESULTS

I believe the complete opening of the outflow system is the key to the encouraging results I have observed with ABiC to date. I compiled data on 86 of my patients with mild to moderate OAG whom I treated with this procedure. Their mean IOP and medication use fell by 19.1% and 78.7%, respectively, 1 year after surgery. Some patients (n = 29) underwent ABiC only, whereas others (n = 57) also had phacoemulsification cataract surgery. Those who had ABiC alone experienced a 24.4% reduction in mean IOP and a 64.5% reduction in medication use 1 year postoperatively. The 57 patients who underwent combined ABiC and cataract surgery had acceptable IOP levels preoperatively.
BLAZING A TRAIL

WATCH IT NOW

Thomas Samuelson, MD, and Steven Vold, MD, discuss the Hydrus II study in this episode of Glaucoma Today Journal Club.

Mahmoud A. Khaimi, MD, demonstrates ab interno canaloplasty to restore the aqueous outflow pathway.

The FDA approval of the Trabectome (NeoMedix) in 2006 introduced the first procedure for microinvasive glaucoma surgery (MIGS), ab interno trabecular ablation. The surgeon uses microelectrocautery to ablate the trabecular meshwork and inner wall of Schlemm canal. Trabectome surgery may be performed independently or in conjunction with other intraocular procedures such as cataract extraction/ IOL placement (see Watch It Now on p. 28). It may be performed on pediatric, adult, pseudophakic, and phakic patients and is an option for treating the spectrum of glaucoma severity (ocular hypertension to end-stage disease).

THE PROCEDURE

With a direct goniolens, the surgeon visualizes the nasal angle structures and inserts the Trabectome’s handpiece, which has built-in continuous irrigation to maintain chamber control and aspiration to optimize visibility during the procedure (see Watch It Now). Next, he or she gently inserts the tip of the Trabectome into the trabecular meshwork and depresses the foot pedal to activate the bipolar (mean, 17.92 mm Hg). Nonetheless, postoperatively, they experienced notable falls in mean IOP and medication use of 16.3% and 88.6%, respectively. This is an impressive improvement considering that their glaucoma was already controlled preoperatively and the primary reason for their surgery was to remove troublesome cataracts. More importantly, these results demonstrate a key strength of ABiC: its ability to deliver effective outcomes in a broad population, including both phakic and pseudophakic patients.

CONCLUSION

By treating the entire outflow system (see Watch It Now), ABiC eliminates the guesswork that limits the efficacy of other MIGS procedures. Furthermore, because ABiC effectively reduces IOP and the medication burden, even for patients with advanced glaucoma, it presents a much-needed stent-free solution for patients with all types of OAG.

3. Khaimi M. Twelve-month follow-up of ab interno canaloplasty as a standalone treatment and in adjunct to cataract surgery for the treatment of primary open-angle glaucoma. Poster presented at: The 27th Annual AOA Meeting; March 9, 2017; Coronado, CA.
electrocautery, which ablates the trabecular meshwork and inner wall of Schlemm canal. The handpiece is advanced through an arc of clear visualization, which is usually between 120º and 180º. This approach ensures that the ends of the ablated tissue are not in apposition to one another, thereby minimizing fibrosis and closure of the opening. This is the key advantage of the Trabectome compared with traditional goniotomy. The procedure avoids risks typically associated with intraocular implants such as erosion, extrusion, infection, malposition, and corneal decompensation.

RESULTS

Dozens of investigators have evaluated the long-term safety and efficacy of the Trabectome in various clinical settings. Typically, postoperative IOP measures in the midteens regardless of the preoperative level. The highest success rates are seen in cases of steroid-induced glaucoma, pseudoexfoliation, and other conditions where the trabecular meshwork is the site of primary pathology. The lowest success rates are in patients with very low IOP targets (8-12 mm Hg). Concurrent cataract extraction is not necessary to achieve a significant IOP reduction.

Prior glaucoma surgery (tube shunt or trabeculectomy) does not affect the outcome of the Trabectome procedure and vice versa. The most common adverse event is transient postoperative hyphema. No unexpected long-term adverse events have been reported after a decade of follow-up.

A recent study looking at the 10-year outcomes of 5,435 cases showed that, at 90 months, IOP had decreased from an average preoperative level of 23.0 ± 7.9 mm Hg to 16.5 ± 3.8 mm Hg and that the number of glaucoma medications dropped from 2.6 ± 1.3 to 1.6 ± 1.3. These results represent an approximately 30% reduction in IOP from baseline, with a significant decrease in medication reliance.

Another study specifically analyzed Trabectome outcomes in steroid-induced glaucoma. The researchers reported that IOP decreased from an average of 33.8 ± 6.9 mm Hg preoperatively to 15.00 ± 3.46 mm Hg at 12 months. The survival rate at 12 months was 93%. This is one of the highest published success rates of any glaucoma procedure and is paired with minimal risks and complications.

CONCLUSION

When ophthalmologists are selecting a MIGS procedure to incorporate into their armamentarium, it is important to choose one that is easy to learn, is low risk, is applicable to a broad population of patients with various pathologies and stages of disease, and has known long-term outcomes. The Trabectome stands apart from other options in that it can be used successfully across the spectrum of disease severity; it may be performed in phakic, pseudophakic, pediatric, and adult patients; and it has the longest proven track record of safety and efficacy of all MIGS procedures. Also worth noting is that no major modifications have been needed or made to the device since the first units were released.

The Kahook Dual Blade

BY MICHAEL D. GREENWOOD, MD

The trabecular meshwork (TM) is thought to be the main site of resistance to aqueous outflow. Incising or removing this tissue should lower this resistance, leading to improved IOP control. Previous methods of simply incising the TM with various instruments, including a microvitreoretinal blade and the Trabectome (NeoMedix), have provided suboptimal IOP lowering, perhaps due to the incomplete removal of tissue or membrane formation across the remaining leaflets with a subsequent increase in IOP.

Rather than just incise the TM, the Kahook Dual Blade (KDB; New World Medical) removes tissue more completely, making the surgically created cleft more resistant to closure and producing more sustained IOP control. The sharp tip of the KDB allows it to pierce the TM

<table>
<thead>
<tr>
<th>TABLE 1. RESULTS FOR ALL EYES</th>
<th>Preoperatively (n = 120)</th>
<th>Day 1 (n = 71)</th>
<th>Week 1 (n = 120)</th>
<th>Month 1 (n = 119)</th>
<th>Month 3 (n = 115)</th>
<th>Month 6 (n = 89)</th>
<th>Month 9 (n = 38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean IOP, mm Hg</td>
<td>18.7 ±6.7</td>
<td>13.0 ±4.5</td>
<td>14.5 ±6.6</td>
<td>14.2 ±4.3</td>
<td>13.5 ±3.9</td>
<td>12.9 ±2.5</td>
<td>12.9 ±4.2</td>
</tr>
<tr>
<td>Mean difference, mm Hg</td>
<td>Reference</td>
<td>-5.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-4.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-4.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-5.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-5.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-5.8&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Mean number medications</td>
<td>1.8 ±1.3</td>
<td>0.7 ±1.1</td>
<td>0.9 ±1.2</td>
<td>0.9 ±1.1</td>
<td>1.0 ±1.1</td>
<td>1.0 ±1.1</td>
<td>0.7 ±0.8</td>
</tr>
<tr>
<td>Mean difference</td>
<td>Reference</td>
<td>-1.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-1.1&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*Courtesy of New World Medical.
<sup>a</sup>Significant at an alpha of 0.05.

<table>
<thead>
<tr>
<th>TABLE 2. RESULTS FOR CATARACT SURGERY COMBINED WITH KAHOOK DUAL BLADE</th>
<th>Preoperatively (n = 71)</th>
<th>Day 1 (n = 71)</th>
<th>Week 1 (n = 71)</th>
<th>Month 1 (n = 71)</th>
<th>Month 3 (n = 70)</th>
<th>Month 6 (n = 57)</th>
<th>Month 9 (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean IOP, mm Hg</td>
<td>17.4 ±5.2</td>
<td>13.3 ±3.9</td>
<td>13.4 ±4.8</td>
<td>13.6 ±3.4</td>
<td>12.6 ±2.6</td>
<td>12.7 ±2.3</td>
<td>12.4 ±3.4</td>
</tr>
<tr>
<td>Mean difference, mm Hg</td>
<td>Reference</td>
<td>-4.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-4.0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-3.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-4.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-4.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-5.0&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Mean number medications</td>
<td>1.6 ±1.3</td>
<td>0.4 ±0.9</td>
<td>0.7 ±1.1</td>
<td>0.7 ±0.9</td>
<td>0.9 ±1.1</td>
<td>0.9 ±1.1</td>
<td>0.6 ±0.8</td>
</tr>
<tr>
<td>Mean difference</td>
<td>Reference</td>
<td>-1.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-1.0&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*Courtesy of New World Medical.
<sup>a</sup>Significant at an alpha of 0.05.
and be seated in Schlemm canal, along which the instru-
ment can be easily guided. The ramp of the KDB elevates
the TM and directs it toward the two blades, which cut the
tissue and leave an intact strip of TM (Figure).

THE PROCEDURE
The KDB procedure can be performed alone or simul-
taneously with cataract surgery through a single clear
corneal incision, and it requires no additional materials
or equipment. First, the surgeon places viscoelastic in the
anterior chamber. The patient’s head is rotated 30º to 45º
away from the surgeon, and the microscope is tilted 30º to
45º toward him or her. The ophthalmologist then places a
direct gonioprism on the cornea and identifies the anatom-
ical landmarks. Next, he or she inserts the KDB via the clear
corneal incision and advances the device along Schlemm
canal in a clockwise or counter-clockwise manner. The KDB
is rotated 180º, the blade is advanced in the opposite direc-
tion to join the previously incised TM, and a free-floating
TM strip is created. This strip is then easily removed by
either a secondary instrument or the irrigation and aspira-
tion handpiece (see Watch It Now on p. 32).

RESULTS
The available data are encouraging. A recent multi-
center, prospective, cohort study included 120 eyes that
were treated with the KDB as a standalone procedure,
combined with cataract surgery, or combined with other
procedures. The eyes in this study had glaucoma ranging
in severity from mild to end-stage.

In all cases, the mean IOP at baseline was 18.7 ±6.7 mm
Hg, and 9 months postoperatively, the mean IOP was 12.9
±4.2 mm Hg (P < .001), a reduction of 5.8 mm Hg or 31.0%.
The mean number of hypotensive medications decreased
from 1.8 ±1.3 to 0.7 ±0.8 at 9 months (P < .001; Table 1).

Seventy-one eyes underwent cataract surgery combined
with the KDB procedure. The baseline IOP in this group
was 17.4 ±5.2 mm Hg, and the mean number of hypoten-
sive medications was 1.6 ±1.3 preoperatively. Nine months
postoperatively, the mean IOP was 12.4 ±3.4 mm Hg, a
decrease of 5.0 mm Hg or 28.7% (P < .001), and the num-
ber of medications decreased to 0.6 ±0.8 (P = .005; Table 2).

The safety profile of the KDB is favorable. The most
common observation is intraoperative blood reflux, which
occurs with many microinvasive glaucoma procedures. It
may result in retained blood in the anterior chamber 1 day
postoperatively but usually clears by the 1-week visit.

1. Jea SY, Francis BA, Vakili, et al. Ab interno trabeculectomy versus trabeculotomy for open-angle glaucoma. Ophthalmo-
log. 2012; 119:36-42.
2. Seglio LD, Soracco JR, Amsar DA, Kahook MY. Preclinical investigation of ab interno trabeculectomy using a novel
presented at: ASRS/ASOA Congress & Symposium; May 5-9, 2017; Los Angeles, CA.
Using a surgical gonioprism to view the angle, I incise the trabecular meshwork with the tip of the Trab360 and advance the probe into Schlemm canal. I like to unroof about 1 clock hour of the trabecular meshwork with the device’s tip and then place it flush with the back wall of the canal before advancing the probe. After it passes 180º, I use a push-pull motion to unroof the trabecular meshwork to achieve a 180º trabeculotomy. I instill a cohesive viscoelastic to tamponade bleeding and reverse the device to perform the same procedure on the other 180º of the angle. I then remove the viscoelastic from the eye with irrigation and aspiration using balanced salt solution on a cannula (Figure 2; see Watch It Now).

RESULTS

Chin and colleagues demonstrated that a 360º trabeculotomy lowers IOP more than a partial trabeculotomy. Based on my initial 8- to 12-month results, my patients’ postoperative IOPs are similar to what Chin et al1 and Grover et al5 have reported for 360º trabeculotomy. There does not seem to be a difference between ab interno and ab externo techniques in terms of IOP lowering.

My patients’ mean IOP measured 19.8 ±6.4 mm Hg preoperatively and 13.5 ±4 mm Hg at final follow-up. Their average number of medications dropped from 1.1 ±1.2 before surgery to 0.2 ±0.5 at final follow-up. I am currently collecting long-term, 3-year data. Postoperative complications have been the same as reported with all of the other
trabeculotomy procedures—primarily transient hyphema that usually resolves within a few days after surgery.

CONCLUSION
The Trab360 is a novel device that can be used to perform a circumferential trabeculotomy. Initial results show it to be safe and efficacious, but long-term follow-up of more patients is needed. Research thus far shows ab interno trabeculotomy to be an important and less invasive method for lowering IOP than a similar procedure with a suture, blade, cautery, or catheter. Moreover, surgery with the Trab360 need not be combined with cataract extraction to be effective or on label. It is my opinion that this device is a more complete and more efficient technique than the other methods of ab interno trabeculotomy currently available.


Excimer Laser Trabeculostomy

BY MICHAEL BERLIN, MD, MS; VIGAN ROKA, MD; MICHAEL RIGGS; AND ULRICH GIERS, MD

Unlike argon and selective laser trabecuoplasty, excimer laser trabeculostomy (ELT; not FDA approved) precisely excises tissue without causing thermal injury to or scarring of the surrounding tissue. This procedure uses a XeCl (308-nm) excimer laser coupled to an intraocular fiber optic delivery system to create long-term anatomic openings that connect the anterior chamber directly to Schlemm canal.

THE PROCEDURE
ELT is performed as an outpatient procedure under topical or peribulbar anesthesia (see Watch It Now). The surgeon creates a paracentesis and then stabilizes the anterior chamber by injecting a viscoelastic. A fiber optic probe is then advanced through the paracentesis, across the anterior chamber, to contact the trabecular meshwork. An optical fiber is required to deliver the 308-nm UV laser radiation energy to circumvent corneal and aqueous humor absorption of this energy. The surgeon visualizes the placement by gonioscopy or via an endoscope. Adequate pulsed photoablative energy is then applied to create the channels (Figure).

In current protocols, the surgeon creates 10 channels in one or two inferior quadrants. A small amount of blood reflux from Schlemm canal confirms each channel’s patency. The surgeon then removes the probe from the eye and exchanges the viscoelastic for balanced salt solution.

Postoperatively, patients administer topical antibiotic and steroid drops for 1 to 2 weeks. The IOP decreases immediately after surgery. The postoperative care of patients undergoing ELT in the European Union generally consists of two to three visits over the course of 1 to 2 months.

CLINICAL RESULTS
Numerous clinical studies have demonstrated ELT’s ability to achieve a long-term reduction in IOP while also decreasing and often eliminating the need for glaucoma medications in phakic and in pseudophakic patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), whether the procedure is performed alone or in combination with cataract surgery. In a study presented in 2013, 46 phakic eyes with medically treated OAG or OHT underwent ELT, and 37 eyes with medically treated OAG or OHT underwent ELT combined with phacoemulsification. The primary outcome measures were mean change in IOP (without washout) and the number of glaucoma medications from baseline. Secondary outcome measures included change in visual acuity (BCVA), surgical complications, and adverse events. Eight years postoperatively, the mean IOP in the ELT-alone group had decreased 29.7% from a preoperative level of 22.9
±5.4 to 16.1 ±3.4 mm Hg (P < .001). In the combined group, the mean IOP decreased 43.4% from a preoperative level of 25.1 ±6.1 to 14.2 ±3.1 mm Hg (P < .001). The number of glaucoma medications for ELT alone changed from 1.6 ±0.7 to 1.2 ±1.2 (P < .152) and, for ELT combined with phacoemulsification, from 1.3 ±0.7 to 1.8 ±0.8 (P < .087).

PNEUMATIC CANALOPLASTY

An additional advantage of ELT is that it enables pneumatic canaloplasty. During ELT, both coaxial endoscopic views and gonioscopic views reveal the expansion of gas bubbles seen coming through the adjacent channel when Schlemm canal is entered at each subsequent ELT site. The phenomenon results from the photoablative conversion of trabecular meshwork tissue into gas. These bubbles are presumed to confirm patency and continuity of fluid flow into and through Schlemm canal. The pressure of this gas may also dilate the canal and the adjacent collector channels to improve aqueous outflow.

CONCLUSION

ELT has been approved for use in the European Union for more than a decade. Unlike alternative microinvasive trabecular meshwork glaucoma surgeries to reduce outflow obstruction, ELT does not require the implantation of foreign bodies or cause coagulative damage. Unlike argon and selective laser trabeculoplasty, which may be performed in an office setting but do not create anatomic outflow channels, ELT is an intraocular procedure performed in a surgical suite. As with other microinvasive glaucoma surgical procedures, the initial learning curve is somewhat steep, but ELT devices that require no gonioscopy or endoscopy are in development.

The rationale for supraciliary outflow as a target for glaucoma treatment has been debated for more than a century. The supraciliary space is delineated by the internal surface of the sclera and the external surface of the choroid. The point of highest resistance is the ciliary body. Physiologically, it is a potential space held captive by a constantly maintained negative hydrostatic pressure. In 1906, surgeons placed horse hair in the supraciliary space to enhance uveoscleral outflow. In 1912, they used silk thread for the same purpose. Ophthalmic surgeons used intraocular instrumentation to induce cyclodialysis clefts to lower IOP. Unfortunately, these techniques were fraught with numerous complications, including bleeding, hypotony, sudden IOP spikes, and frequent failure.\(^1,2\)

Considering the dismal past of surgical procedures involving the supraciliary space, why are newer devices a viable option for glaucoma therapy?

**DESIGNING THE IDEAL SUPRACILIARY DEVICE**

In recent years, doctors and industry have sought to unlock the secrets of the supraciliary space as a means of improving glaucoma management. The FDA approved the CyPass Micro-Stent (Alcon) in 2016,\(^3,4\) and the iStent Supra (Glaukos; Figure) and Miniject (iStar) are in clinical trials. In addition, iStar is exploring implantation of an IOP sensor with the company’s suprachoroidal device.

Nearly a decade of work in the supraciliary space and with these devices has taught me a few critical lessons about the design of supraciliary devices.

**No. 1. An ab interno technique is almost certainly preferable to ab externo implantation of a supraciliary device.** One reason is that implantation via an ab interno approach is less traumatic. Direct visualization of the angle allows surgeons to avoid angle vessels and to place the device between the scleral and choroidal vasculature without inducing significant bleeding. Furthermore, the proximal end of the device can be more easily positioned properly between Schwalbe’s line (where Descemet membrane ends) and the pigmented trabecular meshwork.

**No. 2. The supraciliary device must be made of an anti-inflammatory material.** Gold is less than an ideal material for supraciliary devices, as evidenced by the dense fibrotic membranes that frequently developed over time around the Solx Gold Shunt (Solx; not FDA approved). Materials such as polyimide appear to be less inflammatory in nature, with many patients achieving a sustained reduction in IOP for nearly a decade after microstent placement.

**No. 3. Design appears to be important.** Although the ideal characteristics of a supraciliary microstent have yet to be fully elucidated, the configuration of the device, the size of the supraciliary lake after the implant’s placement, the potential advantage of using adjunctive antifibrotic medications inside the device at implantation, and the potential use of these devices as a means of delivering pharmaceutical products to the retina via the choroidal vasculature seem to hold promise. Already, the
injection of viscoelastic through the CyPass Micro-Stent is being evaluated.

**PERIOPERATIVE CONSIDERATIONS**

Proper surgical technique and perioperative care seem to be critical to optimizing outcomes with suprachoroidal microstents. I have three observations in this area.

**No. 1. Combining the implantation of a suprachoroidal microstent with cataract surgery may maximize success.** Removing the cataract deepens the anterior chamber and thus facilitates the implantation of a suprachoroidal device. I find that hyperinflating the anterior chamber with either a dispersive or a cohesive viscoelastic enhances safety during the microstent’s placement. The proximal end of the device should be positioned between Schwalbe’s line and the pigmented trabecular meshwork. Placing a microstent anterior to Schwalbe’s line increases the risk of late corneal endothelial failure. Devices inserted more posterior than the pigmented trabecular meshwork may become occluded by peripheral iris tissue and fail. Patients with mild open-angle glaucoma may be candidates for a presbyopia-correcting IOL, thus maximizing their refractive outcomes.

**No. 2. Topical glaucoma medication should be discontinued after suprachoroidal microstent surgery.** In clinical trials, it was common for glaucoma medical therapy to stop approximately 1 month before surgery. In my experience, cessation helps to prevent postoperative hypotony as well as potential choroidal effusion and hypotony maculopathy due, at least in part, to the IOP-lowering effect of topical glaucoma medications in the early postoperative period. If IOP begins to rise postoperatively, it may be advisable to prescribe a prostaglandin analogue rather than an aqueous suppressant in order to maintain the aqueous lake within the suprachoroidal space. Uveoscleral outflow must be encouraged to ensure successful long-term outcomes with this type of microinvasive glaucoma surgery (MIGS). Further clinical study is required to confirm or contradict this hypothesis.

**No. 3. Postoperative care is comparable to that after cataract surgery alone.** Patients are typically encouraged to administer prednisolone acetate 1% or dulfoprednate three to four times a day for 4 to 6 weeks postoperatively. Patients with more ocular inflammation than usual, perhaps related to retained cortex, may continue topical steroid therapy for a longer period of time. Loteprednol is likely a reasonable alternative to prednisolone acetate 1% or dulfoprednate. Many surgeons also routinely prescribe a topical nonsteroidal anti-inflammatory drug to prevent postoperative pain and cystoid macular edema.

**CONCLUSION**

Suprachoroidal surgical options enhance uveoscleral outflow and may potentially lower IOP more than trabecular bypass procedures, especially in patients who have a compromised collector system. With proper surgical technique and thoughtful perioperative care, these MIGS devices have promising safety and efficacy profiles for patients with mild to moderate open-angle glaucoma. At this time, understanding of the suprachoroidal space, the ideal suprachoroidal device profile, and perioperative care remains in its infancy. Recent advances are encouraging, however, and continued progress will likely allow surgeons and more of their patients to avoid the risks of filtration blebs in the future.


**CyPass Micro-Stent**

**BY MARC TÖTEBERG-HARMS, MD, FEBO**

Most microinvasive glaucoma surgery (MIGS) procedures target trabecular (conventional) outflow into Schlemm canal but cannot completely overcome the problem of impaired subsequent outflow obstruction (ie, collector channels, deep venous plexus, and episcleral veins). The CyPass Micro-Stent (Alcon; Figure 1) is the first FDA-approved MIGS procedure that targets alternative uveoscleral outflow. This system is independent from trabecular outflow, and a negative pressure gradient between the anterior chamber and the suprachoroidal space is the principle behind this outflow route. The FDA approved the CyPass for implantation through a single clear corneal incision in combination with phacoemulsification cataract surgery plus IOL implantation.

**THE PROCEDURE**

The CyPass procedure is probably one of the easiest MIGS procedures to learn. Because implantation of the device in the suprachoroidal space is intuitive, ophthalmologists who are already familiar with angle surgery should be able to incorporate the CyPass into their practice without much difficulty. For those unfamiliar with angle surgery, the greatest challenge is likely visualization of the anterior chamber angle with a goniolens at the microscope in the operating theater. Miosis is achieved with acetylcholine chloride (10 mg/mL). A crucial step in visualization of the anterior chamber angle is turning the patient’s head approximately 45º away from the surgeon and tilting the microscope by approximately
the same degree in the opposite direction for a temporal approach. A gonioscopic lens with a Thornton ring (eg, Volk Transcend TVG Surgical Goniolens [Volk Optical]) can help the surgeon stabilize and move the eye into the desired direction.

The ophthalmologist introduces the microstent sidewise into the anterior chamber through a corneal incision into the anterior chamber (filled with viscoelastic), turns the implant 90° to align its curvature with that of the sclera, and advances the device toward the opposite side of the eye. He or she should aim directly below the scleral spur (Figure 2). If the guide wire is too close to the iris, the surgeon will observe this tissue moving; if the guide wire is too far away from the iris route, he or she will encounter resistance during implantation. In the correct location, the CyPass glides into the supraciliary space with little to no resistance. The device should be advanced in the supraciliary space but not so far that none of the retention rings is visible in the anterior chamber (Figure 3). The number of rings visualized may vary, depending on the depth of the angle. Ideally, the proximal end of the microstent should be positioned between the pigmented trabecular meshwork and Schwalbe’s line. The guide wire is retracted, and the viscoelastic is washed out using irrigation and aspiration (see Watch It Now on p. 38).

Patients follow a standard postcataract regimen of topical medication, and glaucoma medication may be discontinued and restarted as needed.

RESULTS
The multicenter, interventional, randomized COMPASS clinical trial included 2 years of follow-up. All patients had primary open-angle glaucoma and a mean diurnal unmedicated IOP between 21 and 33 mm Hg. After cataract surgery, subjects were randomized in a 1:3 ratio to either cataract surgery with IOL implantation alone (control group, n = 131) or in conjunction with CyPass implantation (microstent group, n = 374). Both groups had similar baseline characteristics. Sixty percent of control eyes and 77% of eyes that received the CyPass achieved a reduction in unmedicated IOP of at least 20% at 2 years compared to baseline. IOP decreased by 7.4 mm Hg in the microstent group versus 5.4 mm Hg in the control group (P < .001), and 61% of the microstent group and 44% of the control group had an unmedicated IOP between 6 and 18 mm Hg. In addition, 59% of the control subjects versus 85% of microstent subjects were free of medication postoperatively. There were no vision-threatening adverse events related to the microstent, and more than 98% of eyes achieved 20/40 or better BCVA.

In the microstent group, 2.9% of eyes had transient hypotony (IOP \( \leq \) 5 mm Hg); all cases resolved within the first
2 weeks. Whereas hyphema often occurs after trabeculectomy (7.6% in the Tube Versus Trabeculectomy [TVT] study)\(^2\) and with MIGS procedures that bypass the trabecular meshwork (eg, up to 100% after ab interno trabeculectomy with the Trabectome [NeoMedix]),\(^3\) this complication was observed in only 2.7% of eyes that received the CyPass.


**THE SYSTEM**

In November 2016, the FDA approved the Xen Glaucoma Treatment System, which consists of the Xen45 Gel Stent and Xen Injector. The implant is a hydrophilic tube composed of a porcine gelatin cross-linked with glutaraldehyde.\(^3\)

The biocompatibility properties of gelatin are well established and do not cause any foreign body reaction. The optimal diameter of the tube is based on the laminar flow, as calculated using the Hagen-Poiseuille equation, which predicts that flow depends on tube length, inner diameter, and flow viscosity. In an eye with healthy, mobile conjunctiva, not much outflow resistance comes from the subconjunctival space. To avoid a drop in IOP after surgery, all outflow resistance must come from the tube itself, which is approximately 6 mm long and has an inner diameter of about 45 mm. Flow is 0.02 mL/sec or 1.2 mL/min (at a pressure gradient of 5 mm Hg), thus providing approximately 6 to 8 mm Hg of flow resistance, which essentially eliminates hypotony.\(^2\)

**THE PROCEDURE**

Surgery is usually performed under a sub-Tenon block, which achieves effective intraoperative akinesia and analgesia without the possibly sight-threatening complications of retrobulbar injections. Typically, surgeons implant the stent after cataract extraction and IOL placement but before removing the viscoelastic, but Xen surgery can also easily be performed as a solo procedure.

Ab interno glaucoma surgery requires excellent gonioscopic visualization for the ophthalmologist to ensure that the angle is open prior to delivering the implant. The preferred placement of the stent is in the superior-nasal quadrant. The surgeon measures 3 mm from the limbus and places two dye marks in the target area. He or she makes the 1.8-mm main incision opposite the target area and creates a 1-mm sideport 60° to 90° away from the main incision.
Then, the surgeon injects a high-viscosity viscoelastic into the anterior chamber (Figure 1).

To lower the incidence of fibrosis, 0.1 mL of 0.02% mitomycin C may be delivered central to the superior-nasal quadrant and massaged with a Weck-Cel sponge (BVI) to the delivery area. The injector is then inserted through the main incision under gonioscopic control, and the goal is to enter high in the angle. The needle tip needs to exit the sclera 3 ±0.5 mm from the limbus. The surgeon then rotates the bevel 90° toward the 12-o’clock position. With slight forward bias applied to the injector, the stent is delivered. If the correct position is achieved, the injector can be retracted without lateral movement. The surgeon removes the viscoelastic with irrigation and aspiration, during which a distinct, responsive bleb should form, and he or she checks the incisions for leakage.

After implantation, the stent softens in 1 to 2 minutes. In its natural hydrated state, the device is straight, but it conforms to the shape of surrounding tissue. This flexibility is important to avoiding migration and potential erosion (Figure 2).²

RESULTS

Enrollment in the European phase 4 APEX trial has closed, with 216 patients included who have mild to moderate primary open-angle glaucoma and no history of intraocular surgery. The study has two arms: patients receive the Xen45 either as a standalone procedure or in combination with cataract surgery. The first 42 patients who have reached the 12-month visit achieved a mean reduction in IOP of -8.6 mm Hg (-40%) from the medicated preoperative level (21.4±12.8 mm Hg) and a simultaneous mean decrease of -1.9 (-73%) in antiglaucoma medication (2.6-0.7 medications; data on file with Johnson & Johnson Vision).

CONCLUSION

Successful glaucoma surgery must safely provide long-term IOP reduction. In my opinion, subconjunctival drainage of aqueous is the most effective method of achieving sustained lowering of IOP. The combination of an ab interno approach to minimize tissue trauma with a stable, nondegrading, flexible, gelatin stent protects the conjunctiva-Tenon tissue to enhance the surgical outcomes of filtering surgery. The length, lumen diameter, and tube rigidity of the Xen45 Gel Stent restrict flow and avoid hypotony.²

InnFocus MicroShunt

BY HOWARD BARNEBEY, MD

The InnFocus MicroShunt (Santen; not FDA approved) was developed in response to the limitations and challenges of trabeculectomy and glaucoma drainage device procedures. With trabeculectomy, the main problem is the unpredictability of postoperative healing, which presents complications such as conjunctival and Tenon wound fibrosis as well as hypotony, inflammation, shallow chambers, and choroidal detachments. With glaucoma drainage devices, the most common challenges are excessive flow early in the healing process and, late in the postoperative phase, excessive Tenon fibrosis over the silicone plate. In addition, these large drainage devices often require a patch graft to prevent erosion through the conjunctiva.

THE DEVICE

The InnFocus MicroShunt is a minimally invasive, plateless glaucoma drainage microshunt made from an inert biomaterial called SIBS (polystyrene-block-isobutylene-block-styrene; Figure 1). The device shunts aqueous humor from the anterior chamber to the sub-Tenon capsular space (Figure 2). Originally developed as a nonreactive coating material for cardiovascular stents, SIBS has more than a 15-year safety profile in humans and was hypothesized to be an ideal material to address the concerns of glaucoma outflow surgery.¹

THE PROCEDURE

There are few surgical challenges with the MicroShunt, and the learning curve is quick and relatively flat. In brief, similar to a trabeculectomy, creation of a fornix-based conjunctival pocket and the application of mitomycin C (MMC) are important. The crucial step of the procedure (unique and easy to master) is the creation of the scleral tunnel, which has been standardized with a specially designed tunneling blade. The surgeon inserts the blade 3 mm posterior to the surgical limbus and advances until the instrument’s tip is visible in the anterior chamber. The implant is fed into the tunnel until the 1.1-mm-wide supporting fins (4.5 mm distal from the entrance) advance into the distal end of the 1-mm-wide entrance to the tunnel. Flow usually starts immediately and is confirmed with moistening of a dry Weck-Cel sponge (BVI). Rarely, the MicroShunt needs to be primed with balanced salt solution injected over its distal end via a 23-gauge irrigating cannula (Figure 3).

At the conclusion of surgery, the ophthalmologist advances the overlying Tenon and conjunctival tissues to the surgical limbus with care to ensure that the Tenon tissue has not retracted over the device. Both tissues are reapproximated with traditional 9–O or 10–O sutures (Figure 4).

ADVANTAGES AND DIFFERENCES

The MicroShunt procedure is straightforward, requiring no manipulation of the anterior chamber, no special equipment, no scleral dissection, and no sclerectomy or iridectomy. Hemostasis is readily controlled with bipolar cautery.

If the MicroShunt is not placed correctly, it can be simply pulled out and repositioned.

The implant’s unique biomechanical properties and material are well tolerated in the eye and minimize clinically significant fibrotic capsule formation or tissue response at the distal end of the shunt.² Another advantage of this device is the prevention of chronic hypotony with the 8.1-mm-long, 70-µm lumen. In addition, the soft nature of the SIBS material and its ability to take on the shape of the globe eliminate erosion and the need for a patch graft. According to Santen, erosion of the device through the conjunctiva has not been observed to date with any of the more than 1,000 devices implanted over the past decade.
The MicroShunt differs from the Xen45 Gel Stent (Allergan) in several ways. The former is implanted ab externo and does not require the use of a gonioscope, which is often used during ab interno implantation of the Xen. The MicroShunt requires incising the conjunctiva, which would suggest more scarring than with the Xen; both procedures benefit from the use of MMC, however,\textsuperscript{3,4} and a recent report suggests that the Xen requires more postsurgical bleb needling (43%) than trabeculectomy (31%).\textsuperscript{3} With the MicroShunt, postoperative needling of the bleb is rarely required (4.3%).\textsuperscript{5} Possible reasons for minimal scarring with this device are the biocompatibility of the SIBS material, less trauma to the sclera, deep and wide dissection of Tenon capsule from the sclera, a wide application of MMC, and the control of hemostasis. There have been no head-to-head comparisons of the two devices to date, but Santen is currently enrolling subjects in an FDA-sanctioned prospective randomized trial to compare the MicroShunt to trabeculectomy, both with low doses of MMC.

**RESULTS**

In a 3-year study, the MicroShunt was implanted with the application of 0.4 mg/mL MMC in 23 patients.\textsuperscript{5} The procedure had a qualified success rate (IOP $\leq$ 14 mm Hg and IOP reduction $\geq$ 20%) of 95%. The IOP decreased from 23.8 $\pm$ 5.3 to 10.7 $\pm$ 3.5 mm Hg, and the mean number of glaucoma medications per patient dropped from 2.4 $\pm$ 0.9 to 0.7 $\pm$ 1.1.

In another study, 79 patients had an average preoperative, fully medicated IOP of 24.8 $\pm$ 6.1 mm Hg.\textsuperscript{6} Two years after receiving the MicroShunt, the average IOP had decreased by 47% from baseline to 13.0 $\pm$ 4.6 mm Hg, and more than 70% of eyes had an IOP of less than 14 mm Hg. There was a 79% reduction in glaucoma medications per patient, and 74% of subjects were free of topical drug therapy postoperatively.

Santen expects the MicroShunt, pending FDA approval, to become available in the United States in 2019 or 2020. The device has the CE Mark in Europe.

---


BLAZING A TRAIL

Howard Barnebey, MD
medical director and CEO, Specialty Eyecare Centres, Seattle
(206) 621-8407; hbarnebey@specialtyeyecarecentre.com
financial interest: none acknowledged; clinical investigator for the InnFocus MicroShunt FDA phase 1 and 2 studies

Michael Berlin, MD, MS
director, Glaucoma Institute of Beverly Hills, Los Angeles
professor of clinical ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles
berlin@ucla.edu
financial interest: currently none; issued and pending US patents that could apply to FDA-approved ELT

Ulrich Giers, MD
Augen-Praxis-Klinik OWL, Detmold, Germany
financial interest: none acknowledged

Michael D. Greenwood, MD
glaucoma, cornea, cataract, and refractive surgery, Vance Thompson Vision, Fargo, North Dakota
(701) 566-5390; michael.greenwood@vancethompsonvision.com; Twitter @migreenw
financial disclosure: lecturer for Alcon

Leon W. Herndon, MD
professor of ophthalmology, Duke University of Eye Center, Durham, North Carolina
(919) 684-6622; leon.herndon@duke.edu
financial disclosure: consultant to Alcon, Glaukos, and Sight Sciences

Mahmoud A. Khaimi, MD
clinical associate professor of ophthalmology, Dean McGee Eye Institute, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma
(405) 271-1093; mahmoud-khaimi@dmei.org
financial disclosure: consultant to Alcon, Glaukos, and Sight Sciences

Erik L. Mertens, MD, FEBOphth
physician CEO, Medipolis, Antwerp, Belgium
chief medical editor, CRST Europe
+32 3 8282949; emertens@medipolis.be; Twitter @Doktermertens
financial interest: none acknowledged

Sameh Mosaed, MD
professor of ophthalmology and director of glaucoma, The Gavin Herbert Eye Institute, University of California, Irvine
(949) 824-4122; smosaed@uci.edu
financial disclosure: consultant to Alcon

Michael Riggs
Glaucoma Institute of Beverly Hills, Los Angeles
financial interest: none acknowledged

Vigan Roka, MD
Augen-Praxis-Klinik OWL, Detmold, Germany
financial interest: none acknowledged

Steven R. Sarkisian Jr, MD
glaucoma fellowship director, Dean McGee Eye Institute, and clinical professor, University of Oklahoma College of Medicine, Oklahoma City
(405) 271-1093; steven-sarkisian@dmei.org
financial disclosure: consultant to Alcon, Glaukos, New World Medical, and Sight Sciences; holds equity in Sight Sciences; lecturer for Alcon; recipient of research grants from Alcon, Glaukos, and Sight Sciences

Oluwatosin U. Smith, MD
partner physician, Glaucoma Associates of Texas, Dallas
(214) 360-0000; tsmith@glaucomaassociates.com
financial disclosure: consultant to Allergan; medical monitor for Glaukos

Marc Töteberg-Harms, MD, FEBO
glaucoma specialist and attending physician, at the University Hospital Zurich, Department of Ophthalmology, Zurich, Switzerland
clinical instructor and lecturer, University of Zurich, Switzerland
+41 44 255 4993; marc.toeteberg@usz.ch
financial disclosure: consultant/advisor to Allergan; lecture fees/travel reimbursement from Alcon, Allergan, and Index

Steven D. Vold, MD
founder and CEO, Vold Vision, Fayetteville, Arkansas
svold@voldvision.com; Twitter @VoldVision
financial disclosure: consultant to Alcon, Allergan, Ellex, Glaukos, InnFocus, iStar, Ivantis, and NeoMedix